BOS-580-201: A Phase 2a, randomized, blinded, placebo-controlled study of BOS-580 in obese subjects at risk for, or with biopsy-confirmed, nonalcoholic steatohepatitis (NASH)
Inventiva: A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis
AstraZeneca: A Randomised, Double-blind, Placebo-controlled, Multi-centre
Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele
b. Endocrine disorders
ALT-801-203: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects with Nonalcoholic Steatohepatitis (NASH)
For more information on what current clinical trials are available at Kansas City Research Institute or additional information and how to get involved, please contact our office phone at (816)759-2574 or send by email at firstname.lastname@example.org.